Zentalis Pharmaceuticals, LLC（纳斯达克代码：ZNTL）正式公布，其研发的Azenosertib单药疗法将以每日一次400毫克、采用用药五天休两天的给药方案，作为针对周期蛋白E1阳性铂类耐药卵巢癌患者开展关键性临床研究的确定剂量。这一决定基于前期临床试验数据，旨在优化疗效与安全性的平衡，为后续注册研究奠定基础。
Zentalis Pharmaceuticals, LLC（纳斯达克代码：ZNTL）正式公布，其研发的Azenosertib单药疗法将以每日一次400毫克、采用用药五天休两天的给药方案，作为针对周期蛋白E1阳性铂类耐药卵巢癌患者开展关键性临床研究的确定剂量。这一决定基于前期临床试验数据，旨在优化疗效与安全性的平衡，为后续注册研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.